SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The Board of Directors approved the declaration and payment of Interest on Company's Equity (a form of dividend distribution under Brazilian law) in the gross amount of R$ 2,000,000,000.00 (approximately R$ 0.25 per common share), payable on August 6, 2026. This is a material capital distribution to shareholders that would affect investor assessment of the registrant's capital allocation and shareholder returns.
View raw filing on EDGAR →KBR amended and restated severance and change-in-control agreements for six named executive officers, including the CEO and CFO. The amendments materially enhance severance benefits (increasing the cash severance multiple for non-CEO officers from 1.0x to 1.5x base salary plus target bonus), expand the definition of "Good Reason" to include material diminution of compensation or authority, revise "Cause" definitions with notice and cure processes, and add pro-rata vesting provisions for RSUs and equity awards. These are compensatory arrangements that would affect investor assessment of executive retention costs and incentive structures.
View raw filing on EDGAR →The disclosure centers on the results of the Fund's Annual Meeting held June 18, 2026 (adjourned to July 10, 2026), where shareholders elected two Class I Trustees (Brian R. Bruce and John H. Alban) and approved a new investment advisory agreement with Cushing Asset Management, LP. While the section also describes a change of control of the Adviser and entry into the New Advisory Agreement, the primary event disclosed is the shareholder vote and its outcomes, which is material to investors as it affects Fund governance and advisory arrangements.
View raw filing on EDGAR →The disclosure centers on the results of the Fund's Annual Meeting held June 18, 2026 (adjourned to July 10, 2026), where shareholders elected two Class II Trustees (Andrea N. Mullins and John H. Alban) and approved a new investment advisory agreement with Cushing® Asset Management, LP. While the section also describes a change of control of the Adviser (NXG Cushing acquiring a 62% interest from founder Jerry V. Swank), the primary 8-K disclosure is the shareholder vote results and approval of the new advisory agreement. The change of control is disclosed as context for why the new agreement was necessary, but the material event triggering the 8-K filing is the shareholder action.
View raw filing on EDGAR →The company announced a strategic transformation into an AI infrastructure platform, including a ticker symbol change to 'AZIO' (effective July 13, 2026) and a $27.9 million AI infrastructure hosting agreement with Power Champion, scalable to $100 million, representing the company's first long-term contracted AI hosting relationship.
View raw filing on EDGAR →The Board appointed Chris Young, the existing CEO and director, as Chairman of the Board effective July 7, 2026, concentrating additional board leadership responsibility in the existing chief executive.
View raw filing on EDGAR →The filing discloses that Autonomix Medical received a deficiency letter on January 14, 2026 for failing the Nasdaq Bid Price Rule (stock below $1.00 per share for 30 consecutive business days), which triggered delisting risk. Although the company subsequently regained compliance by July 9, 2026, the core event disclosed is the prior delisting threat and its resolution. This is material to investors as it reflects the company's historical struggle to maintain listing standards and demonstrates the company was at material risk of delisting.
View raw filing on EDGAR →Art's-Way Manufacturing issued a press release on July 9, 2026 announcing financial results for the three- and six-month periods ended May 31, 2026, disclosing consolidated sales increases of 23.9% and 26.3% respectively, operating income improvement of 20.2% for the six-month period, and segment-level performance metrics. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the registrant's financial performance and operational trends.
View raw filing on EDGAR →The Board authorized management to "review, consider and pursue strategic alternatives" explicitly including "a merger or disposition of all of its assets" and "selling certain assets, including one or more of its operating businesses." While no transaction has been completed, the authorization to actively pursue M&A activity and strategic transactions is itself a material disclosure that would affect investor assessment of the company's future direction and potential changes to its capital structure or business composition.
View raw filing on EDGAR →George Holding's resignation from the Board of Directors of Trump Media & Technology Group Corp., effective immediately on July 6, 2026, constitutes a director departure. The filing explicitly states his resignation from the Board and all committees, with no dispute cited. Director changes are material to investors' assessment of governance and board composition.
View raw filing on EDGAR →GeoVax Labs received a notice from Nasdaq on July 7, 2026, that it failed to meet the $2,500,000 minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) and does not meet alternative compliance metrics. The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within any extension period granted. This is a direct notice of failure to satisfy a continued listing rule, the core definition of Item 3.01 delisting_risk.
View raw filing on EDGAR →This is a clear auditor change under Item 4.01. HL&B resigned as the Company's independent registered public accounting firm on July 8, 2026, and CohnReznick was appointed as the new auditor on the same date. The filing explicitly discloses the resignation and appointment, with no adverse opinions, disagreements, or reportable events noted, indicating a routine transition driven by HL&B's asset acquisition by CohnReznick.
View raw filing on EDGAR →Skillsoft completed the sale of its Global Knowledge Training LLC business to an affiliate of Enduring Ventures on July 6, 2026, for approximately $5.4 million in initial consideration plus $10.0 million in deferred consideration. This material disposition of a business unit significantly affects the registrant's asset base and future revenue streams.
View raw filing on EDGAR →The filing discloses adjournment of a special stockholder meeting called to vote on the "Asset Sale Proposal" — approval of the sale of substantially all of the Company's assets to Trademark Global, LLC pursuant to an Asset Purchase Agreement dated April 27, 2026. Although the vote was not completed due to insufficient votes at the time of the Special Meeting, the disclosure centers on a material acquisition/disposition event (sale of substantially all assets), which is a change-of-control transaction requiring Item 1.01 or 2.01 disclosure. The adjournment is procedural; the underlying event is the proposed asset sale itself.
View raw filing on EDGAR →United Health Products announced an agreement with NAMSA, a contract research organization, to serve as regulatory sponsor of a clinical study for CelluSTAT Hemostatic Gauze in connection with the company's FDA Premarket Approval application. This is a material operational and strategic milestone—the establishment of a collaboration to advance a critical product through FDA approval—but does not fit the specific categories of M&A activity, debt issuance, workforce reduction, or other named event types. The disclosure centers on a material business partnership and regulatory strategy development.
View raw filing on EDGAR →SUIC Worldwide Holdings completed the acquisition of 51% of Vision Renu Corporation on July 10, 2026, in exchange for 30 million shares (approximately 35% fully-diluted ownership), resulting in Vision Renu becoming a wholly-owned subsidiary and triggering a significant change of control of SUIC with reconstitution of its Board of Directors and appointment of Vision Renu's Chairman as SUIC's new CEO.
View raw filing on EDGAR →The filing discloses entry into a material definitive agreement, but provides insufficient substantive details regarding the agreement's nature, parties, terms, or business purpose to classify it into a specific event category.
View raw filing on EDGAR →The Company exchanged 1,134 shares of Series B Preferred Stock (aggregate stated value $1,134,000) for 8,203,075 shares of common stock in unregistered transactions with Streeterville Capital, LLC on July 8-9, 2026, conducted under Section 3(a)(9) exemption. This is a classic dilutive equity issuance that materially increases common share count and would significantly affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →The disclosure centers on a Board-approved plan to discontinue revenue-generating operations (alcohol monitoring hardware and software) effective July 31, 2026, including workforce reduction (three employees terminated in June 2026), manufacturing cessation, and lease termination. The company estimates ~$50,000 in exit costs and expects to reduce annual operating costs by ~$1.2 million. This is a material operational restructuring with associated exit costs disclosed under Item 2.05, the standard item for workforce reductions and disposal activities.
View raw filing on EDGAR →The filing discloses settlement and cooperation agreements with former management members in connection with a "Compliance and Restitution" initiative involving recovery of improperly issued equity and assets, with coordination among 25 investor parties for "contemplated legal actions." The surrender and cancellation of 455,496 shares (13.7M pre-split) represents material restitution tied to historical corporate misconduct under Board review. While no litigation has yet been filed, the disclosure centers on settlement arrangements, cooperation agreements, and anticipated legal actions arising from historical transactions, which constitutes material litigation-related activity.
View raw filing on EDGAR →The exhibit announces that Basel Medical Group has regained compliance with Nasdaq's minimum bid price rule (Listing Rule 5550(a)(2)) after receiving a non-compliance notice on January 22, 2026. The company's shares had fallen below the $1.00 minimum bid price threshold but have now maintained $1.00 or greater for 10 consecutive business days. This disclosure directly addresses a delisting risk — the company was previously out of compliance with a continued listing standard and has now cured that deficiency. Material to investors as it resolves an immediate threat to continued listing on Nasdaq.
View raw filing on EDGAR →The filing discloses a stock dividend declaration by the Board of Directors on July 9, 2026, whereby holders of Series B Preferred Stock will receive shares of Common Stock based on accrued and unpaid dividends, with approximately 80,463 shares expected to be issued and payment scheduled for July 29, 2026. This is a material dividend distribution event requiring 8-K disclosure under Item 8.01.
View raw filing on EDGAR →The filing discloses positive preclinical study results for MIRA-55, a lead drug candidate, demonstrating favorable oral bioavailability and tissue distribution. This is a material operational/development milestone for a clinical-stage pharmaceutical company, as it advances a key pipeline asset and supports continued development strategy. The event does not fit earnings_release (no financial results), but represents a significant product development achievement material to investors assessing the company's pipeline progress.
View raw filing on EDGAR →Fast Track Group entered into a non-binding memorandum of understanding with Sony Music Entertainment Malaysia for a strategic joint venture partnership to promote artists across Southeast Asia. This is a material operational/strategic partnership announcement that does not fit a specific named category (not M&A, not a discrete contract milestone, but a significant strategic collaboration). The non-binding nature and lack of financial terms disclosed suggest this is an early-stage partnership announcement rather than a completed transaction, making `operational_other` the most appropriate classification.
View raw filing on EDGAR →Fast Track Group announced the successful closing of a $1.5 million senior secured convertible note financing with an institutional investor, plus a $20 million equity line of credit. This constitutes creation of new direct financial obligations under Item 2.03 (Debt Issuance). The convertible note structure and ELOC are material capital-raising transactions that would affect a reasonable investor's assessment of the company's financial position and dilution risk.
View raw filing on EDGAR →This announcement discloses a 35-for-1 share consolidation approved by shareholders at an extraordinary general meeting on June 12, 2026, effective July 20, 2026. While the consolidation is a capital structure change, it is fundamentally a governance matter—a shareholder-approved corporate action affecting share structure and trading mechanics. The stated purpose is to regain compliance with Nasdaq's minimum bid price requirement, making it material to investors assessing the company's listing status and capital structure, though it does not fit the specific categories of exec_appointment, exec_departure, exec_compensation, or shareholder_vote_results (which would apply to voting results, not the announcement of an approved action).
View raw filing on EDGAR →The filing discloses a product enhancement—a third-generation upgrade to NOMAD's Voyager mobile energy storage fleet that increases capacity by up to 56% without changing footprint or deployment time. This is a material operational and strategic development for a company focused on AI energy infrastructure, announced via Item 7.01 (Regulation FD Disclosure) with a press release. While not a named event type (not M&A, not a contract, not a regulatory milestone), it represents a significant product advancement that would affect investor assessment of the company's competitive positioning and market opportunity in the growing data-center battery storage sector.
View raw filing on EDGAR →The filing discloses the appointment of Jeff Hopmayer to MDWerks' Board of Directors, effective June 26, 2026. The press release (Exhibit 99.1) emphasizes Hopmayer's appointment as a pivotal addition to the board during a critical commercial inflection point, highlighting his experience in building and scaling businesses and his role in corporate strategy, partnerships, and M&A. This is a clear executive appointment event, material to investors assessing the company's leadership and strategic direction.
View raw filing on EDGAR →ENvue Medical received a Staff Determination Letter from Nasdaq on July 10, 2026, notifying the company that its closing bid price has been below $1.00 per share for 30 consecutive business days, violating the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for the standard 180-day compliance period due to a prior reverse stock split, and while it intends to request a hearing to appeal, there is no assurance of success. This is a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →The 6-K discloses results of a general meeting of shareholders held on June 30, 2026, with detailed voting tallies for eight proposals: reappointment of six directors (Justin Floyd, Hans Kunz, Nikolaus Senn, Soumaya Hamzaoui, David Bolocan, Prem Parameswaran), reappointment of auditor PKF Littlejohn LLP, and adoption of annual financial statements for the year ended December 31, 2025. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the director and auditor reappointments are material governance matters affecting investor assessment of board composition and audit oversight.
View raw filing on EDGAR →The Company received a Staff Delisting Determination from Nasdaq on July 7, 2026, notifying it of Nasdaq's determination to delist the Company's securities pursuant to Nasdaq Listing Rule IM-5101-4. The Company intends to appeal by requesting an oral hearing before the Nasdaq Hearings Panel, with no assurance the Panel will find the Company in compliance with listing standards. This is a direct delisting notice triggering the appeal process under Rule 5815.
View raw filing on EDGAR →The filing discloses under Item 4.01 that Ainos, Inc. dismissed YCM CPA INC. as its independent registered public accounting firm on July 9, 2026, and simultaneously engaged DLEE Accountancy, Inc. as the new auditor. The company explicitly states there were no disagreements with YCM and no reportable events, indicating a routine auditor transition. This is a classic auditor change event material to investors assessing the registrant's financial reporting oversight.
View raw filing on EDGAR →Min Chul Park, Ph.D., an independent director and member of two Board committees, resigned effective immediately on July 8, 2026. While the Item 5.02 section also discloses voluntary compensation reductions by the CEO and CFO and explores cost-cutting measures including potential asset divestitures and workforce reductions, the primary disclosed action in the Item 5.02 section is Dr. Park's departure from his director and committee positions. The resignation is material as it represents a change in board composition during a period of financial stress and capital-raising efforts.
View raw filing on EDGAR →The filing discloses entry into a Second Amendment to a Member Interest and Asset Exchange Agreement dated July 7, 2026, whereby TLSS will acquire an 80% membership interest in Patriot Glass Solutions, LLC and four nanotechnology patents in exchange for $4.75 million in Series J Preferred Stock. This is a material acquisition transaction with a defined purchase price, closing conditions, and expected closing by August 4, 2026, clearly falling under Item 1.01 (Entry into a Material Definitive Agreement) and constituting M&A activity.
View raw filing on EDGAR →The filing discloses entry into a material definitive agreement (Item 1.01) whereby XMax Inc.'s subsidiary Xmax Beta Holdings Ltd. made an additional subscription of US$8,770,000 in Preamble X Capital I, increasing its ownership interest to more than 99.9%. Item 2.01 confirms completion of this acquisition of assets. The substantial capital commitment and near-total ownership stake constitute material M&A activity, though the exact nature of the underlying investment vehicle warrants some caution on confidence.
View raw filing on EDGAR →Jones Soda issued 7.5 million units at $0.33 per unit for $2.5 million in aggregate gross proceeds, with each unit comprising one common share and one-half warrant. The filing explicitly discloses this under Item 1.01 (Entry into a Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities), and the units were sold to accredited investors under Rule 506(b) and to non-U.S. persons under Regulation S—classic private placement mechanics. The company also announced a concurrent non-brokered offering of up to 2.3 million additional units for $765,000. This is a dilutive equity issuance raising capital through unregistered securities.
View raw filing on EDGAR →The filing discloses new employment agreements for three named executives (CEO Ryan Melsert, CFO Alejandro Flores Arteaga, and COO Steven Wu) effective July 1, 2026, specifying annual salaries, performance-based bonuses, RSU grants, and stock option awards. The Compensation Committee approved these arrangements under Section 16b-3. This is a classic executive compensation disclosure under Item 5.02(e), distinct from appointment or departure since these executives are continuing in their existing roles under revised compensation terms.
View raw filing on EDGAR →The filing discloses multiple capital allocation events: (1) a one-time cash dividend of $0.05 per share (~$1 million aggregate) approved by the Board and payable August 3, 2026; (2) a share repurchase program authorizing up to 10 million shares or 50% of outstanding shares with $20 million allocated through July 2027; and (3) a preliminary balance sheet update following the EMJX acquisition and reverse split. While the filing contains multiple material events, the primary Item 7.01 disclosure centers on the dividend announcement, supported by the repurchase program and balance sheet update. The dividend is material to investors as a direct return of capital from SpaceX investment profits.
View raw filing on EDGAR →Mr. Harry Tang is stepping down from his role as Chief Technology Officer effective July 30, 2026, to become a senior advisor. Although he remains with the company in a different capacity, the principal disclosed action is a departure from an executive officer position (CTO). The filing explicitly states the change was for personal reasons and involved no disagreement with the company, consistent with a voluntary transition rather than a removal.
View raw filing on EDGAR →The filing discloses results of SKYX Platforms Corp.'s 2026 Annual Meeting of Stockholders held on July 8, 2026, under Item 5.07. The company reports voting outcomes for three matters: election of seven directors (Rani R. Kohen, Nancy DiMattia, Gary N. Golden, Efrat L. Greenstein Brayer, Thomas J. Ridge, Dov Shiff, and Leonard J. Sokolow), ratification of M&K CPAS, PLLC as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies for each matter are provided, making this a clear shareholder vote results disclosure.
View raw filing on EDGAR →This exhibit is Form 45-106F1, a Canadian "Report of Exempt Distribution" template used to disclose private placements and exempt offerings of securities. The form's structure and instructions indicate it is filed to report distributions of securities (shares, notes, warrants, etc.) made under exemptions from prospectus requirements in Canadian securities law. While the exhibit shown is the blank form template rather than a completed report with specific transaction details, its presence as an exhibit to a 6-K filing by Avricore Health indicates the company has conducted or is reporting an exempt distribution—a dilutive issuance of equity or debt securities outside registered public offerings. This is material to investors as it affects share dilution and capital structure.
View raw filing on EDGAR →The filing announces Origin Bancorp's plan to issue second quarter 2026 financial results on July 22, 2026, and host a conference call on July 23, 2026, to discuss those results. The press release explicitly states "Origin Bancorp, Inc. Announces Second Quarter 2026 Earnings Release and Conference Call" and identifies the executives who will discuss the results. This is a standard earnings release announcement, material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →The filing discloses preliminary assets under management (AUM) as of June 30, 2026, totaling $183.4 billion, along with a breakdown by investment strategy. While AUM reporting is routine for asset managers, the disclosure includes a material operational development: the termination of a U.S. sub-advisory mandate resulting in approximately $5.7 billion in net outflows from the Value Equity strategy, with an orderly wind-down of the U.S. Value team's strategies expected to continue through Q3. This operational restructuring affecting a significant portion of managed assets qualifies as material to investors assessing the firm's business trajectory.
View raw filing on EDGAR →Nu-Med Plus completed the acquisition of Avid Gold Ltd and its subsidiary Maritimes Gold Corp on July 8, 2026, issuing 4,500,000 Series A Exchange Shares to Avid Gold shareholders, and entered into a Mineral Property Purchase Agreement to acquire six gold properties spanning over 30,900 acres in Atlantic Canada from MegumaGold Corp. This material acquisition represents a significant diversification of the company's business from medical devices into gold exploration and development operations.
View raw filing on EDGAR →The Warrant Amendment materially reduces the exercise price from $16.00 to $1.50 per share for a 30-day period, creating a significant dilutive incentive for the investor to exercise and acquire common stock at a substantially discounted price. This amendment to an existing warrant arrangement effectively facilitates a dilutive equity issuance, as the reduced exercise price makes exercise highly attractive and increases the likelihood of share dilution to existing shareholders.
View raw filing on EDGAR →The disclosure centers on the appointment of Matt Levine as Chief Legal Officer effective July 27, 2026, with detailed background on his prior roles at Clear Secure and Success Academy. While Erin Abrams's departure is also mentioned, the principal action disclosed is the appointment of a new CLO to fill this officer-level position. The appointment of a C-suite executive is material to investors assessing the company's leadership and governance.
View raw filing on EDGAR →Veritone held its Annual Meeting of Stockholders on July 7, 2026, with shareholders voting on six proposals: election of directors (Steelberg and Morales), ratification of CBIZ CPAs P.C. as auditor, advisory vote on executive compensation, amendment to Certificate of Incorporation to increase authorized Common Stock shares from 150 million to 225 million, amendment to the 2023 Equity Incentive Plan to increase authorized shares by 3,000,000, and approval of executive RSU awards.
View raw filing on EDGAR →The Board authorized and stockholders approved an amendment to the Veritone 2023 Equity Incentive Plan increasing authorized shares by 3,000,000 for equity compensation purposes, expanding the company's capacity to grant equity awards to executives and employees.
View raw filing on EDGAR →The filing discloses the appointment of Joshua Chien as an independent director of the Board, effective July 8, 2026, upon recommendation from the Nominating and Corporate Governance Committee. While the Item 5.02 section also mentions compensatory arrangements (annual cash retainer of $60,000 and restricted share unit award of $170,000), the principal disclosed action is the appointment of a director to the Board. This is material as it affects the composition and governance of the company's leadership.
View raw filing on EDGAR →Occidental Petroleum disclosed a summary of "earnings considerations" for Q2 2026 under Item 2.02, providing specific operational metrics including average diluted shares outstanding (1,012.2 million), cash flow impacts from crude oil collar settlements ($156 million negative), and detailed realized prices for oil, NGL, and natural gas across regions. While labeled as preliminary and not a comprehensive earnings estimate, this constitutes a pre-earnings disclosure of material financial and operational results for the quarter, consistent with the earnings_release classification.
View raw filing on EDGAR →